Stryker Stent May Not Be Worth the Stroke Risks, FDA Says

Stryker Corp.’s Wingspan stent may not be worth the risks because the device has no added benefit over drugs used to prevent stroke in patients with narrowed arteries in the brain, U.S. regulators said today.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.